Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to any medication, diet, or supplementation programme.
The term "Ozempic face" entered popular discourse around 2023, borrowed from the same cultural shorthand that gave us "Ozempic body." It describes a constellation of facial changes (hollowed cheeks, deepened nasolabial folds, looser skin around the jaw and neck, and a general loss of the plumpness associated with a youthful face) that some people notice after significant weight loss on GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro).
The phenomenon is real. The name, however, is misleading in one important respect: the changes are not specific to GLP-1 medications. They are a consequence of rapid, substantial fat loss, wherever that fat loss originates.
Understanding this distinction matters because it reframes both the cause and the solutions. "Ozempic face" is not a drug side effect in the conventional sense. It is the face responding to the same biology that governs how skin and subcutaneous fat behave during any form of significant weight reduction. GLP-1 medications have simply brought this longstanding phenomenon to wider attention by enabling more people to lose weight faster than they could through diet and exercise alone.
The face is not held up by bone and muscle alone. A network of discrete fat compartments (the malar fat pad, the buccal fat pad, the deep medial cheek fat, and several periorbital compartments) provides the volumetric scaffolding that gives the midface its lifted, full appearance in youth. These fat pads gradually deflate with age, but they also respond to rapid energy deficit just as visceral and subcutaneous fat elsewhere in the body does.
When total body fat falls sharply, facial fat compartments lose volume proportionally, and sometimes disproportionately, because facial subcutaneous fat has different lipolytic responsiveness than, say, abdominal visceral fat. The result is a face that looks deflated relative to the overlying skin, which still has the surface area it had at the higher weight.
The core problem is a timing mismatch. Adipose tissue can be mobilised relatively quickly in response to sustained caloric deficit. The dermal collagen and elastin matrix that gives skin its firmness and recoil capacity adapts much more slowly.
Collagen synthesis is a metabolically expensive process regulated by fibroblast activity. When the subcutaneous fat layer beneath the dermis shrinks, the skin loses its internal support before it has had time to remodel and tighten. Research on post-weight-loss patients has shown a shift toward type III collagen (an immature, less organised form) at the expense of the structured type I collagen that provides tensile strength. Elastin fibre content in the dermis also measurably decreases following significant weight loss, reducing the skin's ability to retract.
A systematic review of soft tissue facial changes following bariatric and medical weight loss confirmed this pattern across both surgical and pharmacological cohorts, finding that the degree of facial soft tissue change correlated strongly with the total magnitude and speed of weight loss rather than the specific method used.
This point bears emphasis: the faster weight is lost, the less time the dermal matrix has to adapt. A slow, steady reduction of 0.25–0.5 kg per week gives fibroblasts time to remodel. A loss of 1–2 kg per week, achievable on high-dose semaglutide, does not. The skin simply cannot keep pace.
This is why the same 15 kg of weight loss looks different on someone who lost it over two years through diet and exercise versus someone who lost it over five months on Wegovy. The total fat loss may be identical. The skin response is not.
Some researchers have proposed that GLP-1 receptor agonists may exert direct effects on skin beyond simple fat loss. GLP-1 receptors have been identified on adipose-derived stem cells (ADSCs), and there is preliminary in-vitro work suggesting that GLP-1 receptor activation may influence matrix metalloproteinase (MMP) activity, enzymes involved in collagen breakdown and remodelling.
Whether this translates to clinically meaningful additional skin laxity beyond what would be expected from equivalent fat loss achieved by other means is not established. The current weight of evidence points to rate and magnitude of fat loss as the dominant driver, not a direct pharmacological effect on the dermis.
The SEMALEAN study followed patients with obesity on semaglutide 2.4 mg using DEXA body composition analysis and found substantial reductions in total fat mass over 12 months, changes of sufficient magnitude to produce the kind of subcutaneous volume loss that underlies "Ozempic face" in susceptible individuals. Notably, lean mass initially declined before stabilising, suggesting that the composition of weight loss is not uniform over time.
GLP-1 medications are typically titrated upward over several months, and there is clinical flexibility in how aggressively this progression is followed. Patients who prioritise skin and facial outcomes have a rationale for a slower titration: extending the time at lower doses reduces the weekly rate of weight loss, giving skin more time to adapt.
Aiming for 0.5 kg per week rather than 1.0–1.5 kg per week roughly halves the speed of subcutaneous volume loss. This is not a reason to avoid effective treatment, but it is a reasonable discussion to have with a prescribing clinician, particularly for individuals who are starting from a lower BMI or who have pre-existing skin laxity concerns.
Skin is not isolated from the broader composition of weight loss. Lean mass loss, loss of skeletal muscle, compounds the appearance of facial deflation by reducing overall structural support and worsening the metabolic context in which skin remodels.
The evidence on GLP-1 medications and lean mass loss is now well-characterised: data from the STEP 1 and STEP 2 trials found that approximately 39–40% of weight lost on high-dose semaglutide was lean mass. This proportion can be substantially reduced with adequate protein intake and resistance training. For a detailed protocol, see the companion article on preventing muscle loss on Ozempic and GLP-1 medications.
The target protein intake for individuals in active weight loss on GLP-1s is 1.6–2.2 g per kilogram of ideal body weight per day, prioritised at each meal. For the broader evidence base on protein and weight loss in the Australian dietary context, protein intake and weight loss covers the research in depth.
Dietary collagen support, via hydrolysed collagen peptide supplementation and adequate vitamin C intake, provides the substrate and cofactors that fibroblasts need for collagen synthesis. The evidence for oral collagen peptides on skin elasticity is accumulating, with several randomised trials showing improvements in skin hydration, elasticity, and wrinkle depth over 8–12-week supplementation periods.
Vitamin C is an essential cofactor in collagen cross-linking (hydroxylation of proline and lysine residues), and deficiency, even subclinical, impairs collagen synthesis. Adequate dietary vitamin C from whole foods or supplementation is a low-cost, low-risk addition to any skin support protocol.
Glycine-histidine-lysine copper complex (GHK-Cu) is a naturally occurring tripeptide found in human plasma that has attracted significant research interest for its effects on skin biology. Levels of GHK-Cu decline with age, mirroring the decline in skin quality, and topical and systemic administration has been studied in preclinical and clinical contexts.
Research published in the International Journal of Molecular Sciences found that GHK-Cu stimulates collagen, elastin, proteoglycan, and glycosaminoglycan synthesis while simultaneously modulating matrix metalloproteinase activity (the enzyme systems responsible for extracellular matrix breakdown. The same research identified GHK-Cu as a modulator of thousands of human genes, with significant clusters related to skin repair and regeneration pathways. (Pickart and Margolina, 2018) PMC6073405)
In practical terms, topical GHK-Cu preparations are available in cosmeceutical skincare and have shown evidence for reduced fine lines and improved skin density in human trials. Systemic research-grade GHK-Cu investigation is an active area. Those with a research interest in copper peptide biology and skin extracellular matrix mechanisms can explore GHK-Cu and related research-grade peptide compounds used in laboratory settings investigating collagen metabolism, noting that cosmetic and research applications are distinct from clinical interventions.
It is important to note that GHK-Cu skincare is not a validated clinical intervention for "Ozempic face", it is an area of research with biological plausibility in the context of skin laxity, not an established treatment.
Photoageing accelerates collagen breakdown via UV-induced MMP upregulation. During active weight loss, when collagen turnover is already compromised by rapid subcutaneous volume change, consistent broad-spectrum SPF 30+ use is more important than at baseline. Australia's UV index makes this particularly relevant year-round, with daily SPF application warranted even in cooler months.
Smoking cessation is relevant for the same reason: nicotine is vasoconstrictive and directly impairs fibroblast collagen synthesis. The skin of a smoker losing weight rapidly is at compounded disadvantage.
Retinoids (topical vitamin A derivatives) remain among the best-evidenced interventions for stimulating dermal collagen production and improving skin texture. Prescription-strength tretinoin or over-the-counter retinol products applied consistently are a reasonable component of a skin maintenance strategy during active GLP-1 weight loss.
For individuals where preventive strategies have been insufficient, or where weight loss is already complete, several evidence-based options exist.
Dermal fillers, hyaluronic acid-based injectables, directly replace lost volume in facial fat compartments. Results are immediate, reversible with hyaluronidase, and typically last 12–18 months. This is currently the most direct intervention for "Ozempic face" once volume loss has occurred.
Radiofrequency and ultrasound devices (such as Morpheus8 and Ultherapy) stimulate fibroblast activity and neocollagenesis through thermal energy delivery to the dermis and subdermis. Multiple sessions are typically required, and results emerge over 3–6 months as new collagen forms. These devices are better suited for mild-to-moderate laxity than for significant volume deficit.
Biostimulator injectables (poly-L-lactic acid and calcium hydroxylapatite products) work by triggering a fibroblast response to produce new collagen over several months. They are often preferred over repeated fillers for diffuse laxity because they address the underlying structural deficit rather than simply filling space.
For Australians considering these options, a consultation with a cosmetic physician or plastic surgeon experienced in weight-loss skin changes, as opposed to standard ageing, will provide more relevant guidance. The pattern of volume loss is different from typical age-related facial deflation, and experienced practitioners will recognise this distinction when planning treatment.
Most people losing weight on GLP-1 medications will notice some change in facial appearance, particularly if they lose more than 10% of body weight. Whether that change constitutes a problem depends significantly on starting point, rate of loss, age, skin baseline, and individual perception.
For many, particularly those losing weight from a higher starting BMI, the health outcomes of sustained weight reduction substantially outweigh any cosmetic concern. Reduced cardiovascular risk, improved glycaemic control, lower joint load, and improved quality of life are meaningful outcomes that need to be weighed alongside any skin-related effects.
The preventive strategies outlined here (slower titration where clinically appropriate, protein adequacy, resistance training, collagen substrate support, and basic skin health habits) are low-cost and low-risk interventions that can meaningfully reduce the visible effect of rapid fat loss on facial appearance. None of them require forgoing the weight loss itself.
For a broader look at how GLP-1 medications work at the receptor and hormonal level, how GLP-1 agonists work covers the underlying biology in accessible detail.
Emerging research on GLP-1 receptor agonists and alcohol cravings: 2025 RCT data, the reward-pathway mechanism, and what it means for semaglutide users.
Comparing bariatric surgery and GLP-1 medications on efficacy, durability, cost, and risk in Australia today, plus a practical decision framework for 2026.
The SELECT trial showed semaglutide cut MACE by 20% in non-diabetic patients with obesity and CV disease. Mechanisms, findings, and Australian PBS access.